low dose in newborn rats attenuates hyperoxia-induced lung and heart injury at a Angiotensin II type 2 receptor ligand PD123319

[1]  R. Morty,et al.  Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[2]  F. Walther,et al.  Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[3]  L. Leng,et al.  A Critical Regulatory Role for Macrophage Migration Inhibitory Factor in Hyperoxia-Induced Injury in the Developing Murine Lung , 2013, PloS one.

[4]  R. Charnigo,et al.  PD123319 Augments Angiotensin II-Induced Abdominal Aortic Aneurysms through an AT2 Receptor-Independent Mechanism , 2013, PloS one.

[5]  J. Jankowski,et al.  Discovery and Characterization of Alamandine: A Novel Component of the Renin–Angiotensin System , 2013, Circulation research.

[6]  A. Danser,et al.  Angiotensin II type 2 receptor agonists: where should they be applied? , 2012, Expert opinion on investigational drugs.

[7]  B. Uhal,et al.  Angiotensin signalling in pulmonary fibrosis. , 2012, The international journal of biochemistry & cell biology.

[8]  J. Penninger,et al.  Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury , 2012, Journal of Molecular Medicine.

[9]  C. Cheadle,et al.  Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. , 2012, The Journal of clinical investigation.

[10]  H. Chou,et al.  Angiotensin II Type 1 Receptor Antagonist Attenuates Lung Fibrosis in Hyperoxia-Exposed Newborn Rats , 2012, Journal of Pharmacology and Experimental Therapeutics.

[11]  R. Lutter,et al.  Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonist , 2011, The Journal of pathology.

[12]  Zhenqi Liu,et al.  Angiotensin II Receptors Modulate Muscle Microvascular and Metabolic Responses to Insulin In Vivo , 2011, Diabetes.

[13]  J. Dyck,et al.  Activation of Akt protects alveoli from neonatal oxygen-induced lung injury. , 2011, American journal of respiratory cell and molecular biology.

[14]  F. Walther,et al.  Apelin attenuates hyperoxic lung and heart injury in neonatal rats. , 2010, American journal of respiratory and critical care medicine.

[15]  L. P. de Sousa,et al.  Anti-Inflammatory Effects of the Activation of the Angiotensin-(1–7) Receptor, Mas, in Experimental Models of Arthritis , 2010, The Journal of Immunology.

[16]  M. Raizada,et al.  The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. , 2010, American journal of respiratory and critical care medicine.

[17]  T. Unger,et al.  The angiotensin AT2 receptor in left ventricular hypertrophy , 2010, Journal of hypertension.

[18]  R. Fraga-Silva,et al.  Vascular Relaxation, Antihypertensive Effect, and Cardioprotection of a Novel Peptide Agonist of the Mas Receptor , 2010, Hypertension.

[19]  T. Zuberbier,et al.  Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor &kgr;B , 2010, Hypertension.

[20]  R. Steinhorn.  Neonatal pulmonary hypertension , 2010, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[21]  P. Thistlethwaite,et al.  Development and pathology of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[22]  J. L. Hansen,et al.  Functional interactions between 7TM receptors in the Renin-Angiotensin System—Dimerization or crosstalk? , 2009, Molecular and Cellular Endocrinology.

[23]  W. Seeger,et al.  Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia , 2009, European Respiratory Journal.

[24]  S. Abman.  Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. , 2009, Annual review of medicine.

[25]  B. Uhal,et al.  Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[26]  M. Fujimura,et al.  Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice , 2008, Respiratory research.

[27]  D. Newby,et al.  The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. , 2008, Biochemical pharmacology.

[28]  F. Walther,et al.  Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury , 2008, European Respiratory Journal.

[29]  E. Baraldi,et al.  Chronic lung disease after premature birth. , 2007, The New England journal of medicine.

[30]  C. Ferrario,et al.  Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. , 2007, Cardiovascular drug reviews.

[31]  S. Abman.  Recent Advances in the Pathogenesis and Treatment of Persistent Pulmonary Hypertension of the Newborn , 2007, Neonatology.

[32]  J. Pesquero,et al.  Functional expression of kinin B1 and B2 receptors in mouse abdominal aorta. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[33]  J. Mullol,et al.  Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis , 2006, Thorax.

[34]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[35]  A. Tanswell,et al.  Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. , 2004, American journal of respiratory and critical care medicine.

[36]  T. Shinohara,et al.  Identification of a G Protein-coupled Receptor Specifically Responsive to β-Alanine* , 2004, Journal of Biological Chemistry.

[37]  L. Juillerat-Jeanneret,et al.  Angiotensin II Type 2 Receptor–Mediated Vasodilation in Human Coronary Microarteries , 2004, Circulation.

[38]  F. Walther,et al.  Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. , 2004, Free radical biology & medicine.

[39]  Thomas Walther,et al.  Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Nakao,et al.  Angiotensin II Type 2 Receptor Deficiency Exacerbates Heart Failure and Reduces Survival After Acute Myocardial Infarction in Mice , 2003, Circulation.

[41]  A. Davenport,et al.  [125I]‐(Pyr1)Apelin‐13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man , 2001, British journal of pharmacology.

[42]  Shokei Kim,et al.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. , 2000, Pharmacological reviews.

[43]  A. Jobe.  The New BPD: An Arrest of Lung Development , 1999, Pediatric Research.

[44]  A. Tanswell,et al.  α1-Antitrypsin Protects Neonatal Rats from Pulmonary Vascular and Parenchymal Effects of Oxygen Toxicity , 1994, Pediatric Research.

[45]  A. Nishio,et al.  Characterization of muscarinic receptor subtype mediating contraction and relaxation in equine coronary artery in vitro. , 1994, Journal of veterinary pharmacology and therapeutics.

[46]  R. Chambers,et al.  Angiotensin II and the fibroproliferative response to acute lung injury. , 2004, American journal of physiology. Lung cellular and molecular physiology.